Safety of Same-Day Pegfilgrastim Administration in Metastatic Castration-Resistant Prostate Cancer Treated With Cabazitaxel With Or Without Carboplatin

Abstract Introduction Although myeloid growth factors are commonly used to treat metastatic castration-resistant prostate cancer (mCRPC), the optimal timing of administration has not been well studied. We assessed the effects of same-day pegfilgrastim, a neutrophil stimulator, after cabazitaxel trea...

Full description

Saved in:
Bibliographic Details
Published in:Clinical genitourinary cancer 2017-06, Vol.15 (3), p.e429-e435
Main Authors: Bilen, Mehmet Asim, Cauley, Diana H, Atkinson, Bradley J, Chen, Hsiang-Chun, Kaya, Diana H, Wang, Xuemei, Vikram, Raghu, Tu, Shi-Ming, Corn, Paul G, Kim, Jeri
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Anti-VEGF therapy
Carboplatin - administration & dosage
Carboplatin - adverse effects
Cytokine
Disease-Free Survival
Drug Administration Schedule
Filgrastim - administration & dosage
Filgrastim - adverse effects
Hematology, Oncology and Palliative Medicine
Humans
Incidence
Kidney cancer
Male
Middle Aged
Neoplasm Grading
Neutropenia - epidemiology
Polyethylene Glycols - administration & dosage
Polyethylene Glycols - adverse effects
Prostatic Neoplasms, Castration-Resistant - drug therapy
Taxoids - administration & dosage
Taxoids - adverse effects
Therapy trends
Toxicity
Urinary Tract Infections - epidemiology
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Introduction Although myeloid growth factors are commonly used to treat metastatic castration-resistant prostate cancer (mCRPC), the optimal timing of administration has not been well studied. We assessed the effects of same-day pegfilgrastim, a neutrophil stimulator, after cabazitaxel treatment with or without carboplatin in patients with mCRPC. We also evaluated the frequency of urinary tract inflammation during treatment. Patients and Methods Between September 2010 and September 2014, 151 consecutive patients with mCRPC underwent cabazitaxel treatment with or without the addition of carboplatin at a single institution. We assessed absolute neutrophil count recovery, incidence of neutropenia, neutropenic fever, antibiotic usage, treatment delays or discontinuation, dose reduction, and hospitalization with pegfilgrastim administration. Radiologists blinded to therapy reviewed CT scans to detect urinary tract inflammation. Results The median patient age was 69 years (range, 41−88 years), 78% were white, and 54% had a Gleason score ≥9. Median overall survival was 9 months (95% confidence interval, 8−11). One patient (
ISSN:1558-7673
1938-0682
DOI:10.1016/j.clgc.2016.12.003